Synthetic Blood Substitutes And Blood Products: Global Market Poised For Rapid Growth by 2025

March 29, 2025 01:08 AM AEDT | By EIN Presswire
 Synthetic Blood Substitutes And Blood Products: Global Market Poised For Rapid Growth by 2025
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, March 28, 2025 /EINPresswire.com/ -- Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What's behind the rapid growth of the synthetic blood substitutes and blood products market size in recent years?

The synthetic blood substitutes and blood products market size has grown rapidly in recent years. It will grow from $6.55 billion in 2024 to $7.62 billion in 2025 at a compound annual growth rate CAGR of 16.3%. This historic period growth can be attributed to an aging population, increasing demand for blood transfusions, rising demand for safe and contaminant-free blood, growing awareness of blood transfusion risks, and an increased focus on emergency medical care.

Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=21294&type=smp

Where is the synthetic blood substitutes and blood products market headed?

The synthetic blood substitutes and blood products market size is expected to see rapid growth in the next few years. It will grow to $13.76 billion in 2029 at a compound annual growth rate CAGR of 15.9%. This forecast period growth can be attributed to the expanding application in military and disaster response, increasing awareness of alternative blood substitutes, growing prevalence of blood-related disorders, and a rising incidence of trauma and emergency surgeries. Major trends in the forecast period include the development of hemoglobin-based oxygen carriers, regulatory approvals and research, advancements in biotechnology, regenerative medicine advancements, and integration of artificial intelligence AI.

Order Your Report Now For A Swift Delivery: https://www.thebusinessresearchcompany.com/report/synthetic-blood-substitutes-and-blood-products-global-market-report

What are the key drivers of the synthetic blood substitutes and blood products market?
The rising prevalence of chronic diseases is expected to propel the growth of the synthetic blood substitutes and blood products market going forward. Chronic diseases, long-lasting conditions requiring ongoing medical attention, are attributed to factors including an aging population, unhealthy lifestyles, and increased life expectancy. Synthetic blood substitutes and blood products can play a critical role in managing chronic diseases by addressing specific challenges related to blood loss, anemia, and organ function, common in patients with chronic conditions. For instance, in June 2024, the Australian Institute of Health and Welfare reported an increase in deaths due to chronic conditions in Australia, driving the growth of this market.

Who are the key players in the synthetic blood substitutes and blood products market?

Major companies operating in the synthetic blood substitutes and blood products market are Takeda Pharmaceutical Company Limited, Fresenius Kabi AG, Baxter International Inc., Octapharma AG, Green Cross Corporation, Alliance Pharmaceutical Corporation, Hemosol Inc., Sanguine Corporation, Sangart Inc., Biopure Corporation, Tenex Therapeutics, Velico Medical, Hemarina S.A., KaloCyte Inc., Aurum Biosciences Limited, SpheriTech Limited, Dendritech Inc., HbO2 Therapeutics LLC, HemoBioTech Inc., and Somatogen Inc.

What are the emerging trends in the synthetic blood substitutes and blood products market?

Major companies in the market are focusing on developing innovative products, like lab-grown blood vessels, enhancing emergency medical care, improving trauma treatment outcomes, and addressing the global shortage of donor blood and tissues. In December 2024, Humacyte Global, Inc., a US-based clinical-stage biotechnology platform company, received FDA approval for Symvess, an off-the-shelf, bioengineered blood vessel implant for trauma patients, providing a safer alternative to vein harvesting or synthetic grafts.

How is the synthetic blood substitutes and blood products market segmented?

Type: Perfluorocarbon Based Product PFC, Haemoglobin Based Oxygen Carrier, Synthetic Platelet, Recombinant Factor, Blood Expander
Application: Cardiovascular Diseases, Anaemia, Organ Transplant, Injury and Trauma, Other Applications
End-User: Hospitals And Clinics, Blood Banks, Other End users
Perfluorocarbon Based Product PFC: Emulsion-Based Products, Non-Emulsion-Based Products
Haemoglobin Based Oxygen Carrier: Polymerized Hemoglobin-Based Products, Crosslinked Hemoglobin-Based Products
Synthetic Platelet: Platelet Substitutes, Platelet Aggregation Inhibitors
Recombinant Factor: Recombinant Factor VIII, Recombinant Factor IX, Other Recombinant Factors
Blood Expander: Colloid Solutions, Crystalloid Solutions

What does the regional outlook look like for the synthetic blood substitutes and blood products market?

North America was the largest region in the synthetic blood substitutes and blood products market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse More Similar Reports By The Business Research Company:
Anemia And Other Blood Disorder Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report
Blood Transfusion Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report
Stem Cell/Cord Blood Banking Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Contact us:
https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.